Phase 3 ENERGIZE-T Trial Demonstrates Mitapivat Significantly Reduces Transfusion Burden in Adults with Thalassemia

Results from the global, double-blind, randomized, placebo-controlled phase 3 ENERGIZE-T trial, published in The Lancet, indicate that mitapivat significantly reduced the transfusion burden in adults with transfusion-dependent alpha-thalassemia or beta-thalassemia. The drug was generally well-tolerated, showing a favorable benefit-risk profile, addressing a substantial unmet need for disease-modifying therapies in these patient populations.